Acorda Therapeutics, a developer of drugs for the treatment of spinal cord injuries and MS, sliced its range -46% to $6 to $7 from $11 to $13. The offering size remains the same at 5.5 million shares. Banc of America is the lead underwriter on the deal. The deal could price tonight and begin trading on the NASDAQ tomorrow under the symbol "ACOR."
